Video
Dr. Chen on Identifying Malignant T-Cell Signatures in CTCL
Author(s):
Pei-Ling Chen, MD, PhD, discusses findings from a study the multiomics of patients with transformed CTCL that she led at Moffitt Cancer Center.
Pei-Ling Chen, MD, PhD, is a member of the Pathology and Cutaneous Oncology Departments at Moffitt Cancer Center and a member of the Moffitt Cutaneous Lymphoma Multidisciplinary Clinic specializing in the research and treatment of cutaneous T-cell lymphoma (CTCL).
Chen recently published results of a multiomics profiling of 70 FFPE skin biopsies and 16 fresh tissue specimens from 56 patients with transformed CTCL. She and her team sought to elucidate the genomic landscape and identify novel therapeutic vulnerabilities of this disease.
Investigators managed to separate the genomic signature between normal benign immune cells and malignant T cells. In time, she hopes these discoveries. Long term, Chen hopes these discoveries lead to the development of novel therapeutic strategies for CTCL.
